Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology and Cancer Center, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA.
Nature. 2010 Mar 11;464(7286):302-5. doi: 10.1038/nature08782.
Prostate cancer (CaP) progresses from prostatic intraepithelial neoplasia through locally invasive adenocarcinoma to castration-resistant metastatic carcinoma. Although radical prostatectomy, radiation and androgen ablation are effective therapies for androgen-dependent CaP, metastatic castration-resistant CaP is a major complication with high mortality. Androgens stimulate growth and survival of prostate epithelium and early CaP. Although most patients initially respond to androgen ablation, many develop castration-resistant CaP within 12-18 months. Despite extensive studies, the mechanisms underlying the emergence of castration-resistant CaP remain poorly understood and their elucidation is critical for developing improved therapies. Curiously, castration-resistant CaP remains androgen-receptor dependent, and potent androgen-receptor antagonists induce tumour regression in castrated mice. The role of inflammation in castration-resistant CaP has not been addressed, although it was reported that intrinsic NF-kappaB activation supports its growth. Inflammation is a localized protective reaction to injury or infection, but it also has a pathogenic role in many diseases, including cancer. Whereas acute inflammation is critical for host defence, chronic inflammation contributes to tumorigenesis and metastatic progression. The inflammation-responsive IkappaB kinase (IKK)-beta and its target NF-kappaB have important tumour-promoting functions within malignant cells and inflammatory cells. The latter, including macrophages and lymphocytes, are important elements of the tumour microenvironment, but the mechanisms underlying their recruitment remain obscure, although they are thought to depend on chemokine and cytokine production. We found that CaP progression is associated with inflammatory infiltration and activation of IKK-alpha, which stimulates metastasis by an NF-kappaB-independent, cell autonomous mechanism. Here we show that androgen ablation causes infiltration of regressing androgen-dependent tumours with leukocytes, including B cells, in which IKK-beta activation results in production of cytokines that activate IKK-alpha and STAT3 in CaP cells to enhance hormone-free survival.
前列腺癌(CaP)从前列腺上皮内瘤变发展为局部浸润性腺癌,再发展为去势抵抗转移性癌。尽管根治性前列腺切除术、放疗和雄激素剥夺是治疗雄激素依赖性 CaP 的有效方法,但转移性去势抵抗性 CaP 是一种高死亡率的主要并发症。雄激素刺激前列腺上皮的生长和存活,早期 CaP 也是如此。尽管大多数患者最初对雄激素剥夺有反应,但许多患者在 12-18 个月内发展为去势抵抗性 CaP。尽管进行了广泛的研究,但去势抵抗性 CaP 出现的机制仍知之甚少,阐明这些机制对于开发改进的治疗方法至关重要。奇怪的是,去势抵抗性 CaP 仍然依赖于雄激素受体,并且强效的雄激素受体拮抗剂可诱导去势小鼠的肿瘤消退。炎症在去势抵抗性 CaP 中的作用尚未得到解决,尽管有报道称固有 NF-κB 激活支持其生长。炎症是对损伤或感染的局部保护反应,但它在许多疾病中也具有致病性作用,包括癌症。虽然急性炎症对宿主防御至关重要,但慢性炎症会导致肿瘤发生和转移进展。炎症反应性 IkappaB 激酶(IKK)-β及其靶 NF-κB 在恶性细胞和炎症细胞中具有重要的肿瘤促进作用。后者包括巨噬细胞和淋巴细胞,是肿瘤微环境的重要组成部分,但它们的募集机制仍然不清楚,尽管它们被认为依赖于趋化因子和细胞因子的产生。我们发现 CaP 进展与炎症浸润和 IKK-α的激活有关,后者通过 NF-κB 独立的、细胞自主的机制刺激转移。在这里,我们表明雄激素剥夺导致依赖雄激素的肿瘤的浸润,白细胞包括 B 细胞,其中 IKK-β的激活导致细胞因子的产生,这些细胞因子激活 CaP 细胞中的 IKK-α和 STAT3,以增强无激素存活。